As of March 1, the annual Blue March campaign kicks off, emphasizing the importance of colorectal cancer screening—a critical health initiative that resonates deeply with the medical community and the public. Colorectal cancer stands as the second most common cancer in France, with over 47,000 new cases diagnosed each year. In the United States, colorectal cancer affects approximately 150,000 people annually, making it a significant public health concern.

The screening process is open to individuals between 50 and 74 years old. Early detection significantly improves prognosis, as colorectal cancer often develops slowly, leading to many cases being curable if identified early. In fact, 90% of colorectal cancers are curable when detected in their earliest stages, underscoring the importance of routine screening.

However, participation in screening programs remains alarmingly low. In 2022-2023, only 34.2% of eligible individuals in some regions took advantage of the free screening, far short of the recommended 45% participation rate. The regional screening rate was even lower, at 32.7%, leading to approximately 3,600 new cases each year—clear evidence that many cases are detected too late.

Brigitte will, the president of the . Cancers Regional Coordination Center, highlighted the challenges in a recent press conference. “Our concern is that we no longer have the hand on which must be invited. 2024 is a special year of transition,” she explained. As introduced by the government in 2024, health insurance now handles the invitations to screen. It has made the evaluation more problematic. Also, it will be necessary to wait for the end of the year’ to measure the impact of the campaign.”

She sympathized with Brigitte and insists on the dire needs of starting the blue March as well as possible.

She confirmed with.

Experts Weigh In on Screening Challenges

Valérie Zimmerlé, the referent doctor at the Coordination Center, emphasized the importance of early detection and timely intervention. “Prevention allows us to quickly address initial lesions before they progress. Preventive screenings are essential to ensure that patients experience fewer complications and faster recoveries,” Zimmermanné concluded.

Didier Giuly, a general practitioner, expressed concern over the technology being so outdated. 😞”You have to follow up on patients’ screening, he admits there is too much low activity compared to the rest of France hence the importance of starting this Blue March as well”.
That includes all involved in system profiling.

Félix Ferrara, president of the Regional Pharmacies, confirmed that pharmacists, too, can issue the screening kit to patients and provide essential advice.

Help “Step-Up Screening Initiatives in the United States.

The United States has made significant strides in expanding screening initiatives, offering an annual colorectal cancer screening test and advancing the age bracket for routine testing to 45. These steps have resulted in significant improvements in early detection and treatment outcomes.

In the U.S., the guidelines from the American Cancer Society are rigorous and centralized, stating thatScreening for colorectal cancer should begin at age 45 and continue until age 75. This approach is proving effective, with many experts recommending similar strategies in France to bridge the participation gap.

Expanding Screening to Younger Ages

There is a growing trend of younger individuals being diagnosed with colorectal cancer, prompting discussions on whether to lower the screening age. Professor Jean-François Seitz, head of the hepato-gastroenterology and digestive oncology department at La Timone hospital and vice-president of the Coordination Center, stated, “We need to determine where to draw the line for including younger adults in screening programs.”

In the United States, for example, the Centers for Disease Control and Prevention (CDC) reports that colorectal cancer rates among adults under 50 have been rising. Similarly, in France, younger individuals are increasingly affected, making it a pertinent issue.

Counterarguments and Future Directions

Some may argue that expanding screening to younger populations could overburden the healthcare system and lead to unnecessary procedures. However, the Epidemiology department provides data suggesting that targeted screening for high-risk younger populations could be a cost-effective approach, This can also be expediously tackled with a robust digital system to interface.

Not extending screening to a broader age range might miss the opportunity to detect and treat cancer earlier, potentially leading to worse outcomes due to delayed diagnoses. Furthermore, advancements in screening technologies, such as the fecal immunochemical test (FIT) and liquid biopsy, offer more convenient and less invasive options for younger patients.

In conclusion, March marks a pivotal awareness and educational campaign. This year is testing a self-managed database system, thus providing an opportunity to engage communities in conversations about screening. Extension to younger sections of the population is imperative, underlined by a strong emphasis on public communication. By leveraging successful international models and technology-oriented systems improvements, public health officials hope to achieve better adherence to screening guidelines and ultimately reduce the disease burden.